Literature DB >> 16785534

Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.

Rengasamy Asokan1, Jing Hua, Kendra A Young, Hannah J Gould, Jonathan P Hannan, Damian M Kraus, Gerda Szakonyi, Gabrielle J Grundy, Xiaojiang S Chen, Mary K Crow, V Michael Holers.   

Abstract

Human complement receptor type 2 (CR2/CD21) is a B lymphocyte membrane glycoprotein that plays a central role in the immune responses to foreign Ags as well as the development of autoimmunity to nuclear Ags in systemic lupus erythematosus. In addition to these three well-characterized ligands, C3d/iC3b, EBV-gp350, and CD23, a previous study has identified CR2 as a potential receptor for IFN-alpha. IFN-alpha, a multifunctional cytokine important in the innate immune system, has recently been proposed to play a major pathogenic role in the development of systemic lupus erythematosus in humans and mice. In this study, we have shown using surface plasmon resonance and ELISA approaches that CR2 will bind IFN-alpha in the same affinity range as the other three well-characterized ligands studied in parallel. In addition, we show that IFN-alpha interacts with short consensus repeat domains 1 and 2 in a region that serves as the ligand binding site for C3d/iC3b, EBV-gp350, and CD23. Finally, we show that treatment of purified human peripheral blood B cells with the inhibitory anti-CR2 mAb 171 diminishes the induction of IFN-alpha-responsive genes. Thus, IFN-alpha represents a fourth class of extracellular ligands for CR2 and interacts with the same domain as the other three ligands. Defining the role of CR2 as compared with the well-characterized type 1 IFN-alpha receptor 1 and 2 in mediating innate immune and autoimmune roles of this cytokine should provide additional insights into the biologic roles of this interaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785534     DOI: 10.4049/jimmunol.177.1.383

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity.

Authors:  John B Harley; Judith A James
Journal:  Arthritis Rheum       Date:  2010-06

2.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Authors:  Timothy E Quan; Robert M Roman; Benjamin J Rudenga; V Michael Holers; Joseph E Craft
Journal:  Arthritis Rheum       Date:  2010-06

3.  CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent.

Authors:  Keith M Woods; Michael R Pope; Sara M Hoffman; Sherry D Fleming
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

4.  Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.

Authors:  James M Kovacs; Jonathan P Hannan; Elan Z Eisenmesser; V Michael Holers
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

5.  Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.

Authors:  Kendra A Young; Andrew P Herbert; Paul N Barlow; V Michael Holers; Jonathan P Hannan
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

6.  Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis.

Authors:  Maiko Moriyama; Takeshi Fukuhara; Markus Britschgi; Yingbo He; Ramya Narasimhan; Saul Villeda; Hector Molina; Brigitte T Huber; Mike Holers; Tony Wyss-Coray
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

7.  Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.

Authors:  R Herrero; L M Real; A Rivero-Juárez; J A Pineda; Á Camacho; J Macías; M Laplana; P Konieczny; F J Márquez; J C Souto; J M Soria; I Saulle; S Lo Caputo; M Biasin; A Rivero; J Fibla; A Caruz
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

8.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

9.  A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family.

Authors:  Daniel Ricklin; Apostolia Tzekou; Brandon L Garcia; Michal Hammel; William J McWhorter; Georgia Sfyroera; You-Qiang Wu; V Michael Holers; Andrew P Herbert; Paul N Barlow; Brian V Geisbrecht; John D Lambris
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

10.  Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE).

Authors:  Rengasamy Asokan; Nirmal K Banda; Gerda Szakonyi; Xiaojiang S Chen; V Michael Holers
Journal:  Mol Immunol       Date:  2012-08-10       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.